Clinical Trials

To assess the safety and tolerability of RBX2660 in subjects with recurrent CDI who have had prior recurrent CDI that was resolved with antibiotic treatment.

The purpose of this study is to evaluate clinical experience with donor screening for fecal transplant, and to evaluate the outcomes from fecal transplant and understand risk factors for fecal transplant failure and relapse after fecal transplant.

A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness.

The purpose of this study is to evaluate microbiota suspension of intestinal microbes. Patients who have had at least one recurrence of Clostridium Difficile Infection (CDI) after a primary episode and have completed at least one round of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization may be eligible for the study. Subjects may receive a second RBX2660 enema if they are deemed treatment failures following the initial enema per the protocol-specified treatment failure definition.

The purpose of this trial is to examine the effect of Fecal Microbiota Transplantation (FMT) compared with Vancomycin for cure of recurrent C. diff infection (CDI) in solid organ transplant (SOT) recipients in a randomized, controlled clinical trial.

The overarching goal of the FMT registry is to expand knowledge and optimize practice in the transplantation of fecal microbiota or other gut-related-microbiota products.

The aim of this protocol is to create a repository for frozen stool samples from donors of Mayo Clinic Rochester MN, FMT program.  We will collect a stool aliquot from each 50 grams of donor sample that is processed for FMT at Mayo Clinic Rochester.

The purpose of this study is to evaluate if Vancomycin Resistant Enterococci (VRE) can be eradicated in patients with Clostridium Difficile infection (CDI) through treatment with Fecal Microbiota Transplantation (FMT) when FMT is being done to treat recurrent CDI rather than VRE.

The purpose of this trial is to evaluate the effectiveness, safety, and tolerability of a single oral administration of study drug CP101 for the prevention of recurrent Clostridioides difficile Infection (CDI) in adult patients.

This Phase 3 trial will be conducted in 2 parts: a randomized, double-blind, placebo-controlled trial arm (Part A) and an optional open-label treatment arm (Part B). After completing standard-of-care (SOC) CDI antibiotics for their most recent CDI recurrence, patients who meet all eligibility requirements will be randomized to receive either the study drug CP101 or placebo in Part A of the trial.  Patients will be evaluated for CDI recurrence and safety ...